Prolactinoma epidemiology and demographics

Prolactinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Prolactinoma and Pregnancy
Causes
Differentiating Prolactinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Prolactinoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Prolactinoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Prolactinoma epidemiology and demographics
CDC on Prolactinoma epidemiology and demographics
Prolactinoma epidemiology and demographics in the news
Blogs on Prolactinoma epidemiology and demographics</small>
Directions to Hospitals Treating Prolactinoma
Risk calculators and risk factors for Prolactinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Prevelance

Autopsy studies indicate that 6-25% of the U. S. population have small pituitary tumors. Forty percent of these pituitary tumors produce prolactin, but most are not considered clinically significant. Clinically significant pituitary tumors affect the health of approximately 14 out of 100,000 people in United States.

In nonselected surgical series, this tumor accounts for approximately 25-30% of all pituitary adenomas. Some growth hormone (GH)–producing tumors also co-secrete PRL. Microprolactinomas are much more common than macroprolactinomas